GlassScriptPhysician profile
Fang Q Weng
NPI 1407388697
$627.90
in general payments reported to CMS, 2019-2025
13 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.66 · 2022: $137 · 2023: $269 · 2024: $103 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.81 | 2022-2023 | Liletta, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $123.76 | 2021-2025 | Novasure, Acessa Provu System, Fluent Fluid Management System |
| Mayne Pharma Commercial LLC | $57.69 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $42.32 | 2024-2025 | |
| Organon LLC | $38.94 | 2022-2024 | Nexplanon |
| Smith+Nephew, INC. | $33.88 | 2023-2024 | Pico 7, Renasys Touch, Pico |
| Sage Therapeutics, LLC | $33.50 | 2024-2025 | Zurzuvae |
| Pacira Pharmaceuticals Incorporated | $26.89 | 2023 | Exparel |
| Mylan Pharmaceuticals INC. | $18.28 | 2022 | |
| Evofem Biosciences, INC. | $16.59 | 2023 | Phexxi |
| Ethicon US, LLC | $14.82 | 2025 | Enseal, Endopath Xcel |
| Coopersurgical, INC. | $14.27 | 2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.